Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611218 | 1.00 | ACLY (0.53) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4611645 | 0.96 | MMP8 (0.49) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4610642 | 0.88 | ACLY (0.67) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4610646 | 0.88 | ACLY (0.67) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4612655 | 0.88 | ACLY (0.67) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4610371 | 0.84 | ACLY (0.62) | ACLYALDH1A1MMP8MMP12MMP13 | |
| SCHEMBL4611418 | 0.84 | ACLY (0.62) | ACLYALDH1A1MMP8MMP12MMP13 | |
| SCHEMBL4609813 | 0.82 | ALDH1A1 (0.52) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4610710 | 0.82 | ALDH1A1 (0.52) | ACLYALDH1A1HTTMMP8MMP12 | |
| SCHEMBL4609818 | 0.82 | ALDH1A1 (0.52) | ACLYALDH1A1HTTMMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | claimed |
| EP-1981845-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
| WO-2007092558-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | ACLY 2581/4885ALDH1A1 907/4885HTT 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.